Cosentyx (secukinumab) is a medication used to treat several autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. The drug works by targeting and blocking the activity of a protein called interleukin-17A, which is involved in inflammation and immune system responses.
According to Drug Patent Watch [1], no new complications or side effects have been reported for Cosentyx in recent years. However, the drug's label includes warnings about the risk of infections, including tuberculosis and fungal infections, as well as allergic reactions and potential effects on the nervous system, such as multiple sclerosis. Patients taking Cosentyx should be monitored for signs of these and other adverse effects.
A study published in the Journal of Biomedical Science [3] found that Cosentyx was generally well-tolerated by patients with psoriasis and psoriatic arthritis, with few serious adverse events reported. However, the study did note that some patients experienced injection site reactions, such as redness and swelling, as well as gastrointestinal symptoms like nausea and diarrhea.
Another study published in the Journal of the American Academy of Dermatology [2] found that Cosentyx was effective in treating moderate to severe psoriasis, with a high proportion of patients achieving clear or almost clear skin after 12 weeks of treatment. The study also reported that the drug was generally safe and well-tolerated, with no new safety concerns identified.
In summary, while no new complications or side effects have been reported for Cosentyx in recent years, patients taking the drug should be aware of the potential risks and side effects outlined in the drug's label. Overall, studies suggest that Cosentyx is generally safe and well-tolerated, with a high level of effectiveness in treating psoriasis and other autoimmune diseases.
Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923940/
[3] https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-019-0592-z